Cambridge Healthtech Institute’s 11th Annual
Engineering Bispecific Antibodies
Designing New Off-the-Shelf Antibody Therapies
May 7-8, 2020
The universe of bispecific antibody platforms, combinations, strategies and chemistry is growing exponentially and the application of bispecific constructs in immunotherapy is proving to be an extremely effective combination. Fine tuning specificity, calibrating potency while minimizing safety risk are all top priorities of antibody engineers for targets in oncology, immuno-oncology and infectious disease. Early results with new platforms and evolving techniques will be shared. Plan to take part in the premier event in the bispecific antibody community and learn what is next for tackling the biggest challenges facing the field and how to overcome them.
Preliminary Agenda
BISPECIFIC CO-STIMULATORY COMBINATIONS
KEYNOTE PRESENTATION: Providing 4-1BB Co-Stimulation to T Cells for Off-the-Shelf Combination Cancer Immunotherapy
Christian Klein, PhD, Head, Oncology Programs & Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich, Roche Pharma Research & Early Development
Simultaneous Multiple Interaction T Cell Engagers (SMITEs): Improving Bispecific Therapies through T Cell Costimulation
Colin E. Correnti, PhD, Senior Scientist and Director of Protein Sciences, Fred Hutchinson Cancer Research Center
Co-Stimulatory Bispecific Antibodies for Combination Cancer Immunotherapy
Dimitris Skokos, PhD, Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals, Inc.
T-Cell Engaging Bispecific Antibodies: Comparing Pfizer’s Platforms
Javier Chaparro-Riggers, PhD, Executive Director, Biomedicine Design, Pfizer
MULTISPECIFICITY AND COMBINATION STRATEGIES
Rational Combinatorial CAR Designs for Effective Immunotherapy
Mohamad Hamieh, PhD, Research Associate, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Novel Insights into Immune Cell-Mediated Killing of Tumor Cells
Stephen J. Demarest, PhD, Senior Research Fellow, Eli Lilly
LUNCHEON PRESENTATION: Unique in vitro Technologies for R&D of Biologics Including scFv, Fab, IgG, Cyclic Peptide and Bispecific
Takashi Ebihara, PhD, COO, GeneFrontier Corporation
CLINICAL VALIDATION OF PLATFORMS
KEYNOTE PRESENTATION: Trends in Bispecific Antibody Development
Janice M. Reichert, PhD, Executive Director, The Antibody Society
Talk Title to be Announced
Tariq Ghayur, PhD, Distinguished Research Fellow, AbbVie Bioresearch Center
T Cell Therapeutics to Address Hematological Malignancies and Solid Tumors
Tara Arvedson, PhD, Executive Director, Oncology and Inflammation Research, Amgen
TUNING SPECIFICITY – BALANCING POTENCY VS. SIDE-EFFECTS
Immunological Synapses in Human Health and Disease
Salvatore Valitutti, MD, Director, Research, INSERM; Head, Laboratory Molecular Dynamics of Lymphocyte Interactions, Cancer Research Center of Toulouse
A Novel Bispecific Antibody Platform that Elicits Efficient Tumor Lysis with Minimal Cytokine Release in Liquid and Solid Tumors
Nathan Trinklein, PhD, CTO, Discovery, Teneobio
Optimizing Cytolytic Activity and Cytokine Release via Affinity Modulation of CD3-Engaging DART® Molecules for Redirected T Cell Killing
Gundo Diedrich, PhD, Director, Antibody Engineering, MacroGenics, Inc.
Activating and Recruiting T Cells with Bispecific Antibodies and Potency-Optimized Cytokines
John Desjarlais, PhD, CSO, Xencor
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
2020 PROGRAMS
View By:









Emerging Indications for Therapeutic Antibodies
Immunogenicity Case Studies and Clinical Management
Improving Immunotherapy Efficacy and Safety
Engineering Antibody-Drug Conjugates
Gene Therapy: Advancing from Bench to Clinic
Immunogenicity Assessment and Regulatory Approval of Biologics
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Optimizing Bioassays for Biologics
Clinical Progress of Antibody-Drug Conjugates
Characterization for Novel Biotherapeutics
Cell and Gene Therapy Analytics
Engineering Bispecific Antibodies
Protein Expression System Engineering